PTC Therapeutics
PTCT
183 hedge funds and large institutions have $3.14B invested in PTC Therapeutics in 2021 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 85 increasing their positions, 50 reducing their positions, and 40 closing their positions.
126% more call options, than puts
Call options by funds: $11.8M | Put options by funds: $5.25M
70% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 50
0.13% less ownership
Funds ownership: 105.41% → 105.28% (-0.13%)
11% less capital invested
Capital invested by funds: $3.52B → $3.14B (-$380M)
12% less funds holding
Funds holding: 208 → 183 (-25)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
60% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$29.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$25.7M |
| 3 |
Janus Henderson Group
London,
|
+$18.6M |
| 4 |
Bank of New York Mellon
New York
|
+$17.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$69.6M |
| 2 |
BAMCO Inc
New York
|
-$33.6M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$21.3M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$19.7M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$14M |
PTCT Hedge Fund Activity: Q2 2021 in Review
183 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q2 2021, worth a combined $3.14B — down 11% from $3.52B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of PTCT and 16 opened new positions — a net loss of 24 holders — while 50 trimmed existing stakes and 85 added.
The largest buyer was Armistice Capital, adding an estimated $29.8M. The largest seller was AllianceBernstein, cutting an estimated $69.6M.
- 183 institutional investors held PTC Therapeutics (PTCT) as of Q2 2021, down from 208 in Q1 2021.
- Funds reported $3.14B of PTC Therapeutics stock for Q2 2021, down 11% quarter-over-quarter.
- 16 funds opened new PTC Therapeutics positions in Q2 2021 and 40 closed out, a net change of -24 holders.
- The largest PTC Therapeutics buyer in Q2 2021 was Armistice Capital, an estimated $29.8M added.
- The largest PTC Therapeutics seller in Q2 2021 was AllianceBernstein, an estimated $69.6M sold.
Based on aggregated 13F filings for Q2 2021.